Brokerages Expect Melinta Therapeutics Inc (MLNT) Will Post Earnings of -$2.73 Per Share

Share on StockTwits

Wall Street brokerages expect Melinta Therapeutics Inc (NASDAQ:MLNT) to post earnings of ($2.73) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Melinta Therapeutics’ earnings, with the lowest EPS estimate coming in at ($3.59) and the highest estimate coming in at ($1.86). Melinta Therapeutics reported earnings per share of ($4.75) in the same quarter last year, which suggests a positive year-over-year growth rate of 42.5%. The business is scheduled to report its next quarterly earnings results on Tuesday, May 14th.

On average, analysts expect that Melinta Therapeutics will report full year earnings of ($10.31) per share for the current financial year, with EPS estimates ranging from ($13.26) to ($7.91). For the next fiscal year, analysts expect that the company will post earnings of ($5.57) per share, with EPS estimates ranging from ($9.69) to ($2.80). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Melinta Therapeutics.

MLNT has been the topic of several research analyst reports. Zacks Investment Research cut Melinta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. ValuEngine cut Melinta Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 23rd. Gabelli cut Melinta Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 20th. Finally, LADENBURG THALM/SH SH restated a “buy” rating and set a $70.00 target price on shares of Melinta Therapeutics in a report on Tuesday, December 18th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $55.00.

Several institutional investors have recently modified their holdings of the company. Marshall Wace North America L.P. acquired a new position in shares of Melinta Therapeutics during the 3rd quarter worth approximately $48,000. Geode Capital Management LLC boosted its holdings in shares of Melinta Therapeutics by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 418,753 shares of the biotechnology company’s stock worth $331,000 after purchasing an additional 13,337 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Melinta Therapeutics by 11.3% during the 4th quarter. Bank of New York Mellon Corp now owns 142,938 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 14,567 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Melinta Therapeutics by 59.1% during the 4th quarter. Rhumbline Advisers now owns 44,129 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 16,400 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its holdings in shares of Melinta Therapeutics by 23.7% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 90,646 shares of the biotechnology company’s stock worth $358,000 after purchasing an additional 17,360 shares during the last quarter.

MLNT stock opened at $4.58 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.81 and a current ratio of 1.12. Melinta Therapeutics has a 12-month low of $3.20 and a 12-month high of $46.00. The stock has a market capitalization of $51.43 million, a P/E ratio of -0.26 and a beta of 2.22.

About Melinta Therapeutics

Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens.

See Also: Short Selling Stocks and Day Traders

Get a free copy of the Zacks research report on Melinta Therapeutics (MLNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Melinta Therapeutics (NASDAQ:MLNT)

Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Altus Midstream  Downgraded by Zacks Investment Research
Altus Midstream Downgraded by Zacks Investment Research
Veolia Environnement  Cut to Sell at Zacks Investment Research
Veolia Environnement Cut to Sell at Zacks Investment Research
Wedbush Analysts Give Childrens Place  a $130.00 Price Target
Wedbush Analysts Give Childrens Place a $130.00 Price Target
Alimera Sciences’  Buy Rating Reaffirmed at HC Wainwright
Alimera Sciences’ Buy Rating Reaffirmed at HC Wainwright
Texas Roadhouse’s  “Hold” Rating Reiterated at Raymond James
Texas Roadhouse’s “Hold” Rating Reiterated at Raymond James
JPMorgan Chase & Co. Analysts Give MTU Aero Engines  a €225.00 Price Target
JPMorgan Chase & Co. Analysts Give MTU Aero Engines a €225.00 Price Target


 
© 2006-2019 Zolmax.